HUMAN IMUNODEFICIENCY VIRUS INFECTION IN PREGNANCY
Abstract
HIV infection represents one of the major global public health challenges, especially among women of reproductive age. In 2020, there were 1.3 million pregnant women infected with HIV worldwide. Untreated HIV infection in pregnancy carries an increased risk of maternal and perinatal morbidity and mortality. Perinatal transmission of HIV refers to the transmission of the virus from mother to child during pregnancy, childbirth, or puerperium. The aim of this paper is to present the up-to-date information on diagnosis, treatment, and monitoring of pregnancy in HIV-positive women, with reference to the time and mode of delivery, in order to prevent the transmission of the virus from mother to fetus.
The main goals of monitoring and treating HIV infection during pregnancy are the following: preventing the transmission of the virus to the fetus, preserving the mother's health, and providing conditions for a safe delivery. The goal of treatment is to maintain the lowest level of the virus in the blood, especially at the time of delivery, in order to reduce the risk of vertical transmission.
It is recommended to start treatment of HIV infection before pregnancy. Also, regular monitoring of the viral load, the CD4+ lymphocyte count, and blood count, as well as performing liver and kidney function tests, is necessary.
The choice of the time and mode of delivery should not differ in pregnant women with a low viral load, as compared to healthy pregnant women, while in pregnant women with a high viral load, the pregnancy should be ended with elective caesarean section.
HIV infection affects both the pregnant woman and the fetus. Therefore, antenatal, intrapartum, and postpartum monitoring is important. The decision on therapy, as well as the time and mode of delivery, should be individual, and made in accordance with the viral load, the clinical presentation of HIV infection of the mother, and the condition of the fetus.
References
1. Castillo-Chavez C, Cooke K, Huang W, Levin SA. On the role of long incubation periods in the dynamics of acquired immunodeficiency syndrome (AIDS). Part 1: Single population models. J Math Biol. 1989;27(4):373-98. doi: 10.1007/BF00290636.
2. UNAIDS. Global HIV & AIDS Statistics - fact sheet [Internet]. 2021 [Cited: 2022 Jan 11]. Available from: https://www.unaids.org/en/resources/fact-sheet. >
3. González R, Rupérez M, Sevene E, Vala A, Maculuve S, Bulo H, et al. Effects of HIV infection on maternal and neonatal health in southern Mozambique: A prospective cohort study after a decade of antiretroviral drugs roll out. PLoS One. 2017 Jun 2;12(6):e0178134. doi: 10.1371/journal.pone.0178134.
4. World Health Organization. Data on the HIV/AIDS response [Internet]. 2021 [Cited: 2022 Jan 11]. Available from: https://www.who.int/data/gho/data/themes/hiv-aids/data-on-the-hiv-aids-response.>
5. CDC. HIV and Pregnant Women, Infants, and Children [Internet]. 2021 [Cited: 2022 Jan 11]. Available from: https://www.cdc.gov/hiv/group/gender/pregnantwomen/index.html.>
6. Kwalombota M. The effect of pregnancy in HIV-infected women. AIDS Care. 2002 Jun;14(3):431-3. doi: 10.1080/09540120220123829.
7. Tjøtta E, Hungnes O, Grinde B. Survival of HIV-1 activity after disinfection, temperature and pH changes, or drying. J Med Virol. 1991 Dec;35(4):223-7. doi: 10.1002/jmv.1890350402.
8. Abdala N, Reyes R, Carney JM, Heimer R. Survival of HIV-1 in syringes: effects of temperature during storage. Subst Use Misuse. 2000 Aug;35(10):1369-83. doi: 10.3109/10826080009148220.
9. Ball J, Desselberger U, Whitwell H. Long-lasting viability of HIV after patient's death. Lancet. 1991 Jul 6;338(8758):63. doi: 10.1016/0140-6736(91)90063-u.
10. Maiques V, García-Tejedor A, Perales A, Córdoba J, Esteban RJ. HIV detection in amniotic fluid samples. Amniocentesis can be performed in HIV pregnant women? Eur J Obstet Gynecol Reprod Biol. 2003 Jun 10;108(2):137-41. doi: 10.1016/s0301-2115(02)00405-0.
11. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006841. doi: 10.1101/cshperspect.a006841.
12. Magiorkinis G, Angelis K, Mamais I, Katzourakis A, Hatzakis A, Albert J, et al. The global spread of HIV-1 subtype B epidemic. Infect Genet Evol. 2016 Dec;46:169-179. doi: 10.1016/j.meegid.2016.05.041.
13. Ter Schiphorst E, Hansen KC, Holm M, Hønge BL. Mother-to-child HIV-2 transmission: comparison with HIV-1 and evaluation of factors influencing the rate of transmission. A systematic review. Trans R Soc Trop Med Hyg. 2022 May 2;116(5):399-408. doi: 10.1093/trstmh/trab165.
14. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 1993 Mar;57(1):183-289. doi: 10.1128/mr.57.1.183-289.1993.
15. Turville SG, Arthos J, Donald KM, Lynch G, Naif H, Clark G, et al. HIV gp120 receptors on human dendritic cells. Blood. 2001 Oct 15;98(8):2482-8. doi: 10.1182/blood.v98.8.2482.
16. Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):254-8. doi: 10.1073/pnas.94.1.254.
17. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008 Jan;214(2):231-41. doi: 10.1002/path.2276.
18. Wang T, Gong N, Liu J, Kadiu I, Kraft-Terry SD, Schlautman JD, et al. HIV-1-infected astrocytes and the microglial proteome. J Neuroimmune Pharmacol. 2008 Sep;3(3):173-86. doi: 10.1007/s11481-008-9110-x.
19. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994 Jul 22;265(5171):528-30. doi: 10.1126/science.7518614.
20. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature. 1997 Feb 13;385(6617):645-9. doi: 10.1038/385645a0.
21. Al-Husaini AM. Role of placenta in the vertical transmission of human immunodeficiency virus. J Perinatol. 2009 May;29(5):331-6. doi: 10.1038/jp.2008.187.
22. World Health Organization. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance: African region. Switzerland: World Health Organization; 2005. p. 11-2.
23. Gray GE, McIntyre JA. Effect of HIV on women. AIDS Read. 2006 Jul;16(7):365-8, 373-7.
24. Gray GE, McIntyre JA. HIV and pregnancy. BMJ. 2007 May 5;334(7600):950-3. doi: 10.1136/bmj.39176.674977.AD.
25. McGowan JP, Shah SS. Prevention of perinatal HIV transmission during pregnancy. J Antimicrob Chemother. 2000 Nov;46(5):657-68. doi: 10.1093/jac/46.5.657.
26. Bernstein HB, Wegman AD. HIV Infection: Antepartum Treatment and Management. Clin Obstet Gynecol. 2018 Mar;61(1):122-136. doi: 10.1097/GRF.0000000000000330.
27. Burns DN, Nourjah P, Minkoff H, Korelitz J, Biggar RJ, Landesman S, et al. Changes in CD4+ and CD8+ cell levels during pregnancy and post partum in women seropositive and seronegative for human immunodeficiency virus-1. Am J Obstet Gynecol. 1996 May;174(5):1461-8. doi: 10.1016/s0002-9378(96)70589-6.
28. Calvert C, Ronsmans C. The contribution of HIV to pregnancy-related mortality: a systematic review and meta-analysis. AIDS. 2013 Jun 19;27(10):1631-9. doi: 10.1097/QAD.0b013e32835fd940.
29. Žerjav S. Laboratorijska dijagnostika HIV infekcije. Acta Fac Med Naiss. 1999;16:75-80.
30. Chilaka VN, Konje JC. HIV in pregnancy - An update. Eur J Obstet Gynecol Reprod Biol. 2021 Jan;256:484-491. doi: 10.1016/j.ejogrb.2020.11.034.
31. Gilleece DY, Tariq DS, Bamford DA, Bhagani DS, Byrne DL, Clarke DE, et al. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. HIV Med. 2019 Mar;20 Suppl 3:s2-s85. doi: 10.1111/hiv.12720.
32. ACOG Committee Opinion No. 752: Prenatal and Perinatal Human Immunodeficiency Virus Testing. Obstet Gynecol. 2018 Sep;132(3):e138-e142. doi: 10.1097/AOG.0000000000002825.
33. Constantatos SN, Boutall AH, Stewart CJ. Recommendations for amniocentesis in HIV-positive women. S Afr Med J. 2014 Dec;104(12):844-5. doi: 10.7196/samj.8660.
34. Darby A, Sierra Hope J. World Health Organization Guidelines (Option A, B, and B+) for Antiretroviral Drugs to Treat Pregnant Women and Prevent HIV Infection in Infants. Embryo Project Encyclopedia [Internet]. 2021. [Cited: 2022 Feb 11]. Available from: http://embryo.asu.edu/handle/10776/13231.>
35. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al.; IMPAACT 1077BF/1077FF PROMISE Study Team. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med. 2016 Nov 3;375(18):1726-1737. doi: 10.1056/NEJMoa1511691.
36. Balasundaram S, Ranganathan K, Umadevi K, Gunaseelan R, Kumaraswamy N, Solomon S, et al. Oral lesions associated with nevirapine-related Stevens Johnson syndrome: A report of four cases. J Oral Maxillofac Pathol. 2011 Jan;15(1):39-45. doi: 10.4103/0973-029X.80024.
37. Delicio AM, Lajos GJ, Amaral E, Lopes F, Cavichiolli F, Myioshi I, et al. Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study. BMC Infect Dis. 2018 Sep 27;18(1):485. doi: 10.1186/s12879-018-3397-x.
38. Clinical info Hiv. gov. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. What's New in the Guidelines [Internet]. [Updated: 2021 December 30; cited: 2022 January 24]. Available from: https://clinicalinfo.hiv.gov/en/guidelines/perinatal/teratogenicity.>
39. Nielsen-Saines K, Komarow L, Cu-Uvin S, Jourdain G, Klingman KL, Shapiro DE, et al.; ACTG 5190/PACTG 1054 Study Team. Infant outcomes after maternal antiretroviral exposure in resource-limited settings. Pediatrics. 2012 Jun;129(6):e1525-32. doi: 10.1542/peds.2011-2340.
40. Watts DH, Huang S, Culnane M, Kaiser KA, Scheuerle A, Mofenson L, et al. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med. 2011 Mar;39(2):163-70. doi: 10.1515/jpm.2010.139.
41. Knapp KM, Brogly SB, Muenz DG, Spiegel HM, Conway DH, Scott GB, et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J. 2012 Feb;31(2):164-70. doi: 10.1097/INF.0b013e318235c7aa.
42. Money D, Lee T, O'Brien C, Brophy J, Bitnun A, Kakkar F, et al.; Canadian Perinatal HIV Surveillance Program. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study. BJOG. 2019 Oct;126(11):1338-1345. doi: 10.1111/1471-0528.15838.
43. International Perinatal HIV Group; Andiman W, Bryson Y, de Martino M, Fowler M, Harris D, Hutto C, et al. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies. N Engl J Med. 1999 Apr 1;340(13):977-87. doi: 10.1056/NEJM199904013401301.
44. National Institute for Health and Care Excellence. Caesarean birth [Internet]. NICE; 2021 [Updated: 2021 Mar, cited: 2022 Jan 24]. Available from: https://www.nice.org.uk/guidance/cg132.>
45. Peters H, Francis K, Harding K, Tookey PA, Thorne C. Operative vaginal delivery and invasive procedures in pregnancy among women living with HIV. Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:295-299. doi: 10.1016/j.ejogrb.2016.12.016.
46. Cotter AM, Brookfield KF, Duthely LM, Gonzalez Quintero VH, Potter JE, O'Sullivan MJ. Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapy. Am J Obstet Gynecol. 2012 Dec;207(6):482.e1-5. doi: 10.1016/j.ajog.2012.10.862.
47. Pogliani L, Erba P, Nannini P, Giacomet V, Zuccotti GV. Effects and safety of delayed versus early umbilical cord clamping in newborns of HIV-infected mothers. J Matern Fetal Neonatal Med. 2019 Feb;32(4):646-649. doi: 10.1080/14767058.2017.1387896.
48. Rabe H, Gyte GM, Díaz-Rossello JL, Duley L. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes. Cochrane Database Syst Rev. 2019 Sep 17;9(9):CD003248. doi: 10.1002/14651858.CD003248.pub4.
49. McMahon JM, Myers JE, Kurth AE, Cohen SE, Mannheimer SB, Simmons J, et al. Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS. 2014 Sep;28(9):462-74. doi: 10.1089/apc.2013.0302.
50. Mmeje O, van der Poel S, Workneh M, Njoroge B, Bukusi E, Cohen CR. Achieving pregnancy safely: perspectives on timed vaginal insemination among HIV-serodiscordant couples and health-care providers in Kisumu, Kenya. AIDS Care. 2015;27(1):10-6. doi: 10.1080/09540121.2014.946385.
51. Savasi V, Parisi F, Oneta M, Laoreti A, Parrilla B, Duca P, et al. Effects of highly active antiretroviral therapy on semen parameters of a cohort of 770 HIV-1 infected men. PLoS One. 2019 Feb 21;14(2):e0212194. doi: 10.1371/journal.pone.0212194.
52. Semprini AE, Levi-Setti P, Bozzo M, Ravizza M, Taglioretti A, Sulpizio P, Albani E, Oneta M, Pardi G. Insemination of HIV-negative women with processed semen of HIV-positive partners. Lancet. 1992 Nov 28;340(8831):1317-9. doi: 10.1016/0140-6736(92)92495-2.
53. Ethics Committee of American Society for Reproductive Medicine. Human immunodeficiency virus (HIV) and infertility treatment: a committee opinion. Fertil Steril. 2015 Jul;104(1):e1-8. doi: 10.1016/j.fertnstert.2015.04.004.
54. U.S. Department of Health & Human Services/U.S. Food & Drug Administration. Truvada for PrEP Fact Sheet: Ensuring Safe and Proper Use [Internet]. 2012 [Cited: 2022 Feb 24]. Available from: https://www.fda.gov/media/83586/download.>
55. Clinical info Hiv. gov. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Pre-exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods [Internet]. 2021 [Updated: 2021 Dec; cited: 2022 Jan 24]. Available from: https://clinicalinfo.hiv.gov/en/guidelines/perinatal/teratogenicity.>
56. Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, et al.; Partners PrEP Study Team. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014 Jul 23-30;312(4):362-71. doi: 10.1001/jama.2014.8735.
